Want to see AU:OPT full AI Analyst Report?

Opthea (OPT) Price & Analysis

42 Followers

OPT Stock Chart & Stats

AU$0.60

-AU$0.04(-5.10%)

At close: Jan 09 4:00 PM EST

AU$0.60

-AU$0.04(-5.10%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.62

Previous CloseN/A

Volume897.04K

Average Volume (3M)0.00

Market Cap

AU$20.52M

Enterprise ValueAU$774.17M

Total Cash (Recent Filing)AU$48.22M

Total Debt (Recent Filing)AU$245.88M

Price to Earnings (P/E)2.9

Beta2.08

Next Earnings

Aug 28, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding1,367,978,100

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)-3.65

Price to Sales (P/S)29392.74

P/FCF Ratio-4.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$200.00K

Bulls Say, Bears Say

Bulls Say

Differentiated Lead Candidate (sozinibercept)Sozinibercept’s distinct mechanism (VEGF-C/D inhibition) complements anti-VEGF-A therapy and represents a durable scientific differentiation. If clinical success is achieved, this could materially expand treatment efficacy, support combination-label strategies, and attract long-term partnerships or licensing given complementary mode of action.

Late-stage Clinical Development FocusExecution of late-stage trials reduces technical uncertainty versus early discovery programs and shortens the pathway to regulatory milestones or commercialization. This positions the company for near-to-intermediate term partnering, milestone revenues, and clearer strategic options versus purely preclinical peers.

Low Leverage — Debt Eliminated In FY2025Elimination of debt removes fixed interest obligations and reduces short-term insolvency risk, giving management more flexibility to negotiate partnerships or equity financings. This structural reduction in leverage improves survivability during protracted clinical programs even while burn remains high.

Bears Say

Persistent Heavy Cash BurnSustained operating cash outflows of ~-159M per year indicate chronic negative cash generation and a reliance on external funding. Over multiple quarters this creates dilution risk, constrains strategic flexibility, and makes long-term program completion contingent on successful financings or partnerships.

Negative Equity And Shrinking Asset BasePersistently negative equity and a sharp fall in assets reflect accumulated losses and a weakened capital base. This structural weakness limits borrowing capacity, increases creditor/partner scrutiny, and raises the probability of dilutive raises or unfavorable financing terms under stress.

Minimal, Volatile Revenue And Large Recurring LossesVery low and volatile revenue with recurring large net losses typifies a pre-commercial biotech that cannot self-fund growth. Until regulatory approval or a licensing deal delivers stable revenue, ongoing negative margins and significant R&D spend will likely persist, pressuring capitalization and strategic options.

Opthea News

Opthea Shareholders Approve Name Change at Extraordinary Meeting

Opthea ( ($AU:OPT) ) just unveiled an update. Opthea Limited has received shareholder approval at an Extraordinary General...

2d ago

Opthea Director Jeremy Levin Boosts Stake With New Options and Share Purchase

Opthea ( ($AU:OPT) ) has shared an update. Opthea director Jeremy Levin has significantly increased his equity exposure...

10d ago

JAF Capital exits substantial holding in Opthea

Opthea ( ($AU:OPT) ) just unveiled an update. JAF Capital Pty Ltd has ceased to be a substantial...

12d ago

Opthea director Katherine Connell increases shareholding with on‑market purchase

An announcement from Opthea ( ($AU:OPT) ) is now available. Opthea director Katherine Connell has increased her stake...

16d ago

BNY Mellon Group Exits Substantial Shareholding in Opthea

Opthea ( ($AU:OPT) ) has issued an update. The Bank of New York Mellon Corporation and its related...

17d ago

Opthea Schedules Online Market Update for Investors

Opthea ( ($AU:OPT) ) has provided an announcement. Opthea Limited announced it will deliver a corporate market update...

26d ago

Opthea relaunches on ASX with rare lung disease push for OPT-302

An update from Opthea ( ($AU:OPT) ) is now available. Opthea will be reinstated to trading on the...

1M ago

Opthea calls virtual extraordinary general meeting for July 2026

Opthea ( ($AU:OPT) ) just unveiled an update. Opthea Limited has scheduled an extraordinary general meeting to be...

1M ago

ASX Flags Delisting Risk for Long-Term Suspended Companies Over Reporting Delays

The latest announcement is out from Opthea ( ($AU:OPT) ). The Australian Securities Exchange has released an update...

3M ago

Opthea Swings to Profit as Net Tangible Assets Turn Positive

Opthea ( ($AU:OPT) ) has issued an announcement. Opthea reported a sharp turnaround in its half-year results to...

4M ago

Opthea terminates COAST trial, announces ShORe trial misses endpoint

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline...

1y ago

OPT

Opthea downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Opthea (OPT) to Perform from Outperform. Published first on TheFly – the ultimate source for real-time,...

1y ago

OPT

Opthea downgraded to Market Perform from Outperform at Leerink

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform. Published first on TheFly – the...

1y ago

OPT

Opthea cut to Market Perform at Leerink on failed sozinibercept trial

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12....

1y ago

OPT

OPT FAQ

What was Opthea Limited’s price range in the past 12 months?

Opthea Limited lowest share price was AU$0.01 and its highest was AU$0.61 in the past 12 months.

What is Opthea Limited’s market cap?

Opthea Limited’s market cap is AU$20.52M.

When is Opthea Limited’s upcoming earnings report date?

Opthea Limited’s upcoming earnings report date is Aug 28, 2026 which is in 55 days.

How were Opthea Limited’s earnings last quarter?

Opthea Limited released its earnings results on Mar 01, 2026. The company reported AU$0.263 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.263.

Is Opthea Limited overvalued?

According to Wall Street analysts Opthea Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Opthea Limited pay dividends?

Opthea Limited does not currently pay dividends.

What is Opthea Limited’s EPS estimate?

Opthea Limited’s EPS estimate is 0.

How many shares outstanding does Opthea Limited have?

Opthea Limited has 1,367,978,100 shares outstanding.

What happened to Opthea Limited’s price movement after its last earnings report?

Opthea Limited reported an EPS of AU$0.263 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Opthea Limited?

Currently, no hedge funds are holding shares in AU:OPT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Opthea Stock Smart Score

Neutral

Fundamentals

Return on Equity

44.23%

Trailing 12-Months

Asset Growth

-83.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opthea Limited

Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.